PartnershipJul 21, 2026, 07:07 AM
Akari Therapeutics Partners with Whitehawk on ADC Research
AI Summary
Akari Therapeutics, an oncology biotechnology company, announced a strategic research collaboration with Whitehawk Therapeutics. The partnership will focus on preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk's topoisomerase I inhibitor (TOP1i) ADC platform. Akari will lead the research, which aims to assess dual payload compatibility and synergies to guide future development decisions and potential broader collaborations. The collaboration is expected to commence immediately, with interim data updates anticipated as studies progress.
Key Highlights
- Akari Therapeutics announced a strategic research collaboration with Whitehawk Therapeutics.
- The collaboration will evaluate Akari's PH1 spliceosome-modulating payload technology.
- It will be combined with Whitehawk's topoisomerase I inhibitor (TOP1i) ADC platform.
- Akari will lead the design, execution, and evaluation of the research activities.
- Initial preclinical studies will assess dual payload compatibility and synergies.
- Interim data updates are anticipated as studies progress.
- The collaboration aims to guide future development decisions and potential broader opportunities.
Price Impact
More from AKTX